Literature DB >> 9816279

Characterization of folate receptor from normal and neoplastic murine tissue: influence of dietary folate on folate receptor expression.

S B Gates1, L G Mendelsohn, K A Shackelford, L L Habeck, J D Kursar, L S Gossett, J F Worzalla, C Shih, G B Grindey.   

Abstract

Membrane-associated folate receptors (FRs) have been detected in many mammalian species, and multiple isoforms have been identified. The pharmacological properties of FRs from murine kidney, liver, and six murine tumors were characterized. Murine kidney expressed primarily folate-binding protein 1, analogous to human FR-alpha, whereas murine liver expressed predominantly folate-binding protein 2, analogous to human FR-beta. Five of six murine tumors expressed high-affinity FRs with pharmacological properties consistent with folate-binding protein 1 isoform expression. Restriction of dietary folate resulted in significant changes in the FR expression in most murine tissues. Kidney and tumor FRs showed a decreased affinity for folic acid, suggesting a change in isoform expression in response to a low folate diet. Density of the FR in the kidney decreased, and, in contrast, density of the FR in all tumors increased. The response of the liver to a low folate diet was unique in that there were no detectable changes in affinity or density of liver FR. Changes in dietary folate that modulate FR isoform expression may have relevance for cancer patients treated with antifolates.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9816279

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  10 in total

Review 1.  Mechanistic Target of Rapamycin Is a Novel Molecular Mechanism Linking Folate Availability and Cell Function.

Authors:  Elena Silva; Fredrick J Rosario; Theresa L Powell; Thomas Jansson
Journal:  J Nutr       Date:  2017-06-07       Impact factor: 4.798

2.  Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol.

Authors:  L G Mendelsohn; C Shih; R M Schultz; J F Worzalla
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  Does folic acid supplementation prevent or promote colorectal cancer? Results from model-based predictions.

Authors:  E Georg Luebeck; Suresh H Moolgavkar; Amy Y Liu; Alanna Boynton; Cornelia M Ulrich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-06-06       Impact factor: 4.254

4.  The reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation. RFC as a double edged sword in folate homeostasis.

Authors:  Ilan Ifergan; Gerrit Jansen; Yehuda G Assaraf
Journal:  J Biol Chem       Date:  2008-05-22       Impact factor: 5.157

5.  Preclinical evaluation of light-activatable, bispecific anti-human CD3 antibody conjugates as anti-ovarian cancer therapeutics.

Authors:  Stephen Thompson; John Dessi; Colin H Self
Journal:  MAbs       Date:  2009-07-19       Impact factor: 5.857

6.  Adaptive transport of folic acid across renal epithelia in folate-deficient rats.

Authors:  Nissar Ahmad Wani; Jyotdeep Kaur
Journal:  J Physiol Sci       Date:  2012-08-04       Impact factor: 2.781

7.  Folate and one-carbon metabolism nutrients from supplements and diet in relation to breast cancer risk.

Authors:  Sonia S Maruti; Cornelia M Ulrich; Emily White
Journal:  Am J Clin Nutr       Date:  2008-12-30       Impact factor: 7.045

8.  Decreased activity of folate transporters in lipid rafts resulted in reduced hepatic folate uptake in chronic alcoholism in rats.

Authors:  Nissar Ahmad Wani; Ritambhara Nada; Krishan Lal Khanduja; Jyotdeep Kaur
Journal:  Genes Nutr       Date:  2012-09-07       Impact factor: 5.523

9.  Mechanism of intestinal folate transport during folate deficiency in rodent model.

Authors:  Nissar Ahmad Wani; Shilpa Thakur; Jyotdeep Kaur
Journal:  Indian J Med Res       Date:  2012-11       Impact factor: 2.375

10.  Radiolabeled RNA Nanoparticles for Highly Specific Targeting and Efficient Tumor Accumulation with Favorable In Vivo Biodistribution.

Authors:  Hongzhi Wang; Peixuan Guo
Journal:  Mol Pharm       Date:  2021-07-02       Impact factor: 5.364

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.